Multiple Myeloma and Plasma Cell Disorders
Clinical development activities include relapsed or refractory multiple myeloma and broader plasma cell disorders, with attention to patients whose disease has returned or no longer responds to prior treatment.
- Multiple Myeloma
- Relapsed or Refractory Disease
- Plasma Cell Disorders
The research focus in this area centers on therapeutic options for hematologic malignancies arising from abnormal plasma cells.
B-cell Malignancies
Heidelberg Pharma AG is also involved in studies for relapsed/refractory B-cell blood cancers, addressing aggressive disease settings in which standard treatment options have been exhausted.
- B-cell Blood Cancers
- Relapsed/Refractory B-cell Malignancies
- Hematologic Cancer
This area reflects interest in targeted approaches for lymphoid cancers with limited remaining therapeutic choices.
Oncology Clinical Development
The sponsor’s clinical research portfolio is concentrated in oncology, with work spanning difficult-to-treat blood cancers and advanced malignant hematology.
- Oncology
- Malignant Hematology
- Blood Cancer
Its clinical development program is oriented toward therapies for patients with advanced disease and high unmet medical need.
Therapeutic Innovation in Antibody-Based Cancer Treatment
Research activity includes investigation of novel cancer therapeutics for hematologic tumors, with emphasis on emerging treatment concepts in targeted oncology.
- Targeted Cancer Therapy
- Antibody-Based Treatment
- Hematologic Tumors
The funded studies support development efforts in cancers that require more selective treatment approaches.
